|
Delayed
London S.E.
08:17:58 2026-08-12 EDT
|
5-day change | 1st Jan Change | ||
| 68.00 GBX | -0.73% |
|
-2.44% | +3.03% |
| 06-30 | EARNINGS AND TRADING: Made Tech forecast revenue ahead of forecast | AN |
| 06-04 | Venture Life buys two US healthcare brands for USD28 million | AN |
| Market Cap | 83.45M 113M 97.7M 91.46M 157M 10.75B 160M 1.07B 420M 5.38B 423M 414M 17.96B | P/E 2026 * |
-29.8x | P/E 2027 * | 18.2x |
|---|---|---|---|---|---|
| Enterprise Value | 48.75M 65.86M 57.07M 53.43M 91.74M 6.28B 93.28M 627M 245M 3.14B 247M 242M 10.49B | EV / Sales 2026 * |
0.97x | EV / Sales 2027 * | 1.16x |
| Free-Float |
82.81% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Venture Life Group plc
| 25-08-05 | Venture Life : Result of General Meeting | PU |
| 25-07-16 | Venture Life : Notice of General Meeting | PU |
| 25-06-30 | Venture Life : 2025 AGM Results | PU |
| 25-06-06 | Venture Life : 2025 Notice of AGM | PU |
| 24-06-04 | Venture Life : 2024 AGM Results | PU |
| 1 day | -0.73% | ||
| 1 week | -2.44% | ||
| Current month | -2.44% | ||
| 1 month | +2.26% | ||
| 3 months | +20.35% | ||
| 6 months | -3.55% | ||
| Current year | +3.03% |
| 1 week | 68 |  | 70 |
| 1 month | 66 | | 71 |
| Current year | 54 | | 72 |
| 1 year | 52 | | 72 |
| 3 years | 27 | | 72 |
| 5 years | 23 | | 95 |
| 10 years | 20 | | 118 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeremy Randall
CEO | Chief Executive Officer | 62 | 2010-02-28 |
Daniel Wells
DFI | Director of Finance/CFO | 39 | 2021-11-30 |
Peter Jackson
CTO | Chief Tech/Sci/R&D Officer | - | 2025-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeremy Randall
BRD | Director/Board Member | 62 | 2005-12-11 |
Carl Dempsey
BRD | Director/Board Member | - | 2018-09-19 |
Daniel Wells
BRD | Director/Board Member | 39 | 2021-12-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 2/12/26 | Buy | 2,959 | 0.0024% | |||
| 1/9/26 | Sell | Founder | 10,000 | 0.0079% | ||
| 1/9/26 | Sell | Founder | 173,015 | 0.1366% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.73% | -2.44% | +12.86% | +117.60% | 113M | |
| -0.72% | +3.16% | +88.73% | +124.31% | 1,083B | |
| -0.40% | +0.04% | +49.15% | +48.58% | 626B | |
| -0.65% | +0.91% | +25.07% | +63.15% | 442B | |
| -1.27% | -0.55% | +47.20% | +36.95% | 363B | |
| -1.36% | -0.45% | +28.75% | +36.27% | 295B | |
| -1.06% | -2.76% | +5.57% | +5.31% | 248B | |
| +0.07% | +1.21% | +44.84% | +58.16% | 224B | |
| -2.71% | +1.38% | -6.91% | -51.82% | 210B | |
| +0.43% | +2.90% | +12.97% | +69.80% | 168B | |
| Average | -0.69% | +2.35% | +30.82% | +50.83% | 365.92B | |
| Weighted average by Cap. | -0.64% | +4.29% | +48.02% | +63.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 50.35M 68.02M 58.95M 55.18M 94.75M 6.49B 96.35M 647M 254M 3.25B 255M 250M 10.83B | 54.7M 73.89M 64.04M 59.95M 103M 7.05B 105M 703M 275M 3.53B 277M 271M 11.77B |
| Net income | -3.21M -4.34M -3.76M -3.52M -6.05M -414M -6.15M -41.29M -16.18M -207M -16.3M -15.94M -691M | 5.3M 7.15M 6.2M 5.8M 9.96M 682M 10.13M 68.04M 26.66M 341M 26.86M 26.27M 1.14B |
| Net Debt | -34.7M -46.88M -40.62M -38.03M -65.3M -4.47B -66.4M -446M -175M -2.24B -176M -172M -7.47B | -20.2M -27.29M -23.65M -22.14M -38.01M -2.6B -38.65M -260M -102M -1.3B -102M -100M -4.35B |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-12 | GBX 68.00 | -0.73% | 29,626 |
| 26-08-11 | GBX 68.50 | 0.00% | 31,908 |
| 26-08-10 | GBX 68.50 | -0.44% | 193,505 |
| 26-08-07 | GBX 68.80 | 0.00% | 37,070 |
| 26-08-06 | GBX 68.80 | -1.29% | 45,981 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.6850GBP
Average target price
1.500GBP
Spread / Average Target
+118.98%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VLG Stock
Select your edition
All financial news and data tailored to specific country editions
